Aegle Therapeutics

Aegle Therapeutics Corp. is a biotechnology startup founded in 2013 and based in the United States. The company's focus is on developing extracellular vesicle (EV) therapies to address rare and serious diseases and disorders with significant unmet medical needs. Aegle's proprietary platform technology allows for the safe isolation of native extracellular vesicles from stem cells. These EVs carry complex assemblies of biologic molecules and have the potential to induce a wide variety of effects in recipient cells, including regenerative healing, inflammation reduction, and immune system modulation. The company's last investment of $3.00M came in the form of a Convertible Note investment on 12 April 2022 from Deepwork Capital. Aegle Therapeutics' areas of focus for its EV therapy include dermatology, immunology-based diseases, and protein deficient disorders. The potential applications span across a broad range of indications in multiple therapeutic areas. For more information about Aegle Therapeutics, interested parties can visit the company's website at www.aegletherapeutics.com.